Autolus Therapeutics (NASDAQ:AUTL) Sets New 12-Month Low - Here's What Happened

Shares of Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $1.92 and last traded at $1.97, with a volume of 124566 shares trading hands. The stock had previously closed at $2.03.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on AUTL shares. The Goldman Sachs Group upgraded Autolus Therapeutics from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Redburn Atlantic upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target on the stock in a report on Friday, November 15th. Finally, Needham & Company LLC restated a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, January 13th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $10.40.

Autolus Therapeutics Stock Performance

The stock has a market cap of $514.88 million, a P/E ratio of -1.60 and a beta of 2.02. The firm has a 50-day moving average price of $2.35 and a 200-day moving average price of $3.31.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter in the previous year, the firm posted ($0.26) EPS. On average, research analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Dumont & Blake Investment Advisors LLC purchased a new position in shares of Autolus Therapeutics during the fourth quarter valued at approximately $35,000. Arkadios Wealth Advisors bought a new stake in Autolus Therapeutics in the 4th quarter worth approximately $47,000. Capstone Investment Advisors LLC purchased a new stake in Autolus Therapeutics during the 3rd quarter valued at $51,000. Daiwa Securities Group Inc. lifted its holdings in shares of Autolus Therapeutics by 55.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock valued at $56,000 after buying an additional 8,479 shares during the period. Finally, Avanza Fonder AB purchased a new position in shares of Autolus Therapeutics in the 4th quarter worth $75,000. Institutional investors own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.